<DOC>
	<DOCNO>NCT01169376</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor identify learn biomarkers related cancer . PURPOSE : This research study study biomarkers young patient neuroblastoma .</brief_summary>
	<brief_title>Biomarkers Young Patients With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To discover therapeutically relevant driver mutation high-risk pediatric neuroblastoma . Secondary - To identify set highly annotated neuroblastoma specimen ( primary tumor cell line ) comprehensive genomic analysis , validation study , resequencing effort , future functional assay . - To define genome-wide DNA copy number allelic status least 300 high-risk 50 low-risk neuroblastoma primary untreated tumor , 30 human neuroblastoma-derived cell line . - To define genome-wide methylation profile neuroblastoma minimum 200 high-risk case . - To define genome-wide microRNA expression profile neuroblastoma minimum 200 high-risk case . - To define genome-wide RNA expression signature , include splice variation , tumor cell line study . - To identify mutation candidate therapeutic target use stag resequencing strategy ultimate genome-scale next generation resequencing 3 genome 200 high-risk case : neuroblastoma genome transcriptome well pair constitutional genome . - To characterize relapsed high-risk neuroblastoma genome epigenome . OUTLINE : This multicenter study . Previously collect sample analyze define genome-wide DNA copy number allelic status ; define genome-wide methylation profile high-risk neuroblastoma case ; define genome-wide microRNA expression profile high-risk neuroblastoma case ; define genome-wide RNA expression relate gene expression DNA copy number gene polymorphism , DNA methylation , microRNA expression ; resequence three genome : neuroblastoma genome , transcriptome , pair constitutional genome ; characterize relapse high-risk neuroblastoma genome epigenome . PROJECTED ACCRUAL : A total 300 tumor sample patient high-risk disease , 50 tumor sample patient low-risk primary neuroblastoma , 30 human neuroblastoma-derived cell line accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Registered COGANBL00B1 Neuroblastoma Biology Study CCG POG precursor Sufficient highquality tumor material available propose study meet follow criterion : Tissue histopathologic review &gt; 70 % tumor cell section adjacent area use nucleic acid preparation Matched normal cell ( blood uninvolved bone marrow ) available ≥ 5 μg DNA available ≥ 5 μg RNA available ≥ 200 mg tissue available Tumor sample must meet 1 follow criterion : Highrisk tumor With without MYCN amplification With without tumor progression relapse ( ≥ 2.5 year follow ) Patients age 18 month 5 year Lowrisk tumor Primary neuroblastoma Stage I disease ( completely resect ) No event ≥ 3 year follow Cell line represent diverse highrisk genetics include without MYCN amplification clinical course ( diagnosis relapse ) PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
</DOC>